COVID‐19 vaccine (mRNA BNT162b2) and COVID‐19 infection‐induced thrombotic thrombocytopenic purpura in adolescents. Issue 6 (4th April 2022)

• Record Type: Journal Article
• Authors: Vorster, Luna; Kirk, Susan E.; Muscal, Eyal; Despotovic, Jenny M.; Cohen, Clay T.; Sartain, Sarah E.
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 6(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-04
• Subjects: acquired TTP -- COVID‐19 -- TTP -- vaccination; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29681
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: The mRNA COVID‐19 vaccine and COVID‐19 infection caused by the SARS‐CoV‐2 virus may be immunologic triggers for the development of thrombotic thrombocytopenic purpura (TTP). There is not yet literature that discusses TTP induced by COVID‐19 vaccination or infection in pediatric or adolescent patients. We describe three adolescents presenting with TTP (both de novo and relapsed disease) following administration of the Pfizer COVID‐19 vaccine or after COVID‐19 infection. Our observations demonstrate that the Pfizer‐BioNTech mRNA vaccine and COVID‐19 infection can act as triggers for the development/relapse of both congenital and acquired TTP.